Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the ...
Reaffirms New Drug Application (NDA) first quarter 2025 submission guidance Confirms no additional adult clinical trials are necessary prior to NDA submission Commenced pediatric trial in the U.S. and ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback